Key Developments: Becton Dickinson and Co (BDX)

BDX on New York Consolidated

114.06USD
15 Sep 2014
Price Change (% chg)

$0.35 (+0.31%)
Prev Close
$113.71
Open
$113.77
Day's High
$114.27
Day's Low
$113.02
Volume
663,752
Avg. Vol
633,077
52-wk High
$120.66
52-wk Low
$98.30

Search Stocks

Latest Key Developments (Source: Significant Developments)

Becton Dickinson and Co reaffirms FY 2014 guidance
Thursday, 31 Jul 2014 06:00am EDT 

Becton Dickinson and Co:Reaffirms FY 2014 revenue guidance range of 4.5 to 5.0 pct. On a reported.Expects FY 2014 revenue growth of 4.0 to 4.5 pct.Reaffirms FY 2014 diluted earnings per share from continuing operations to be between $6.22 and $6.25.Says foreign currency-neutral basis, adjusted diluted earnings per share growth is expected to be between 10.0 to 10.5 pct, or 11.0 to 11.5 pct excluding the incremental impact of the medical device tax.Reported revenues of $8.1 bln in FY 2013.FY 2014 EPS of $6.25 - Thomson Reuters I/B/E/S.  Full Article

Becton Dickinson and Co declares quarterly dividend
Tuesday, 22 Jul 2014 04:05pm EDT 

Becton Dickinson and Co:Declares quarterly dividend of 54.5 cents per common share.payable on Sept. 30, to holders of record on Sept. 9.  Full Article

Becton Dickinson and Co 's BD Medical signs agreement for installation of BD Cato
Tuesday, 17 Jun 2014 08:30am EDT 

Becton Dickinson and Co:Says BD Medical, segment of company announced an agreement with The University of Texas MD Anderson Cancer Center.For BD Cato, system that enhances safety and workflow efficiency in medication preparation via gravimetric and barcoding technology.MD Anderson Cancer Center will be first healthcare institution in U.S. to implement BD Cato System and will be incorporating the system into its outpatient infusion pharmacies, including community-based locations.  Full Article

Becton Dickinson and Co announces low-volume clinical laboratories now have access to advanced data management with new blood culture instrument connectivity
Wednesday, 11 Jun 2014 09:00am EDT 

Becton Dickinson and Co:Launch of BD BACTEC FX40 Blood Culture System with connectivity to BD EpiCenter Microbiology Data Management System.This communication enables access to advanced reporting capabilities, connectivity to the hospital's Laboratory Information System (LIS) and access to the unique BD Blood Volume Monitoring Software.  Full Article

Becton Dickinson and Co declares dividend
Tuesday, 20 May 2014 04:22pm EDT 

Becton Dickinson and Co:Declared a quarterly dividend of 54.5 cents per common share.Payable on June 30 to holders of record on June 9.  Full Article

Becton Dickinson And Co's BD MAX enteric bacterial panel receives FDA clearance to detect the common causes of bacterial gastroenteritis
Wednesday, 7 May 2014 11:06am EDT 

Becton Dickinson And Co:Says its BD Diagnostics announced the availability of the FDA-cleared BD MAX Enteric Bacterial Panel for use on the BD MAX System.BD MAX Enteric Bacterial Panel is an IVD test detecting DNA from C ampylobacter spp. ( jejuni and coli), Salmonella spp., Shigella spp. / Enteroinvasive E. coli (EIEC) as well as stx 1 and stx 2 genes in stool specimens.  Full Article

Becton Dickinson And Co reaffirms FY 2014 revenue guidance and raises FY 2014 EPS guidance
Thursday, 1 May 2014 06:02am EDT 

Becton Dickinson And Co:Reaffirms FY 2014 revenue guidance range of 4.5-5.0 pct.Raises FY 2014 diluted earnings per share from continuing operations to be between $6.14-$6.17, or $6.22-$6.25 excluding the impact of the previously mentioned second quarter adjustments.Says foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 10.0-10.5 pct, or 11.0-11.5 pct excluding the incremental impact of the medical device tax.Reported revenues of $8.1 bln in FY 2013.FY 2014 EPS of $6.23 - Thomson Reuters I/B/E/S.  Full Article

Becton Dickinson And Co's BD Biosciences launches new point-of-care system for HIV/AIDS patients
Thursday, 24 Apr 2014 08:30am EDT 

Becton Dickinson And Co:BD Biosciences segment of Becton Dickinson And Co launch of BD FACSPresto Near Patient CD4 Counter system.Sya that provides absolute and percentage results of CD4 T lymphocytes and hemoglobin (Hb) concentration in whole blood samples to stage and monitor HIV/AIDS patients.Wit intuitive language-independent graphical touchscreen interface and on-board videos to guide operation, the BD FACSPresto system can be easily transported and operate off a rechargeable battery, enabling patients even in remote settings to receive critical CD4 testing.  Full Article

Becton Dickinson And Co raises low end of prior FY 2014 EPS guidance
Tuesday, 4 Feb 2014 06:00am EST 

Becton Dickinson And Co:Now expects FY 2014 EPS to be between $6.19 and $6.22.  Full Article

Becton Dickinson And Co declares dividend
Tuesday, 28 Jan 2014 02:00pm EST 

Becton Dickinson And Co:Says it has declared a quarterly dividend of $0.545 per common share payable on Mar. 31 to holders of record on Mar. 10.  Full Article

Search Stocks